COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 3rd May 2020. As a result, our offices will now be closed till 3rd May 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details.,, Mob. 8826373757, 8826859373, 9910947804

Print ISSN:-2394-2789

Online ISSN:-2394-2797


Current Issue

Year 2020

Volume: 7 , Issue: 1

Article Access statistics

Viewed: 843

Emailed: 0

PDF Downloaded: 197

International Journal of Pharmaceutical Chemistry and Analysis

Aromatase Inhibitors: A Safer Approach for the Treatment of Breast Cancer

Full Text PDF Share on Facebook Share on Twitter

Author Details : Chiragkumar J. Gohil, Malleshappa N. Noolvi

Volume : 2, Issue : 4, Year : 2015

Article Page : 192-198

Suggest article by email


Breast cancer is the second leading cause of cancer death in women. About two-thirds of breast cancers are termed hormone-dependent breast cancer, which contains estrogen receptors (ER) and requires estrogen for tumor growth. Aromatase, the enzyme involved in the last step of the biosynthesis of estrogens from androgens, are potential targets for the prevention and treatment of this type of breast cancer. Aromatase inhibitors can markedly suppress plasma estrogen levels by inhibiting aromatase. However, these compounds inhibit aromatase activity in a global fashion and thus could adversely impact sites where estrogen is required for normal function. This drawback has encouraged researchers to develop new drugs that can selectively inhibit aromatase for breast cancer.

How to cite : Gohil C J, Noolvi M N, Aromatase Inhibitors: A Safer Approach for the Treatment of Breast Cancer. Int J Pharm Chem Anal 2015;2(4):192-198

Copyright © 2015 by author(s) and Int J Pharm Chem Anal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (